| Petrides, Georgios |
NCT03926520: Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) |
|
|
| Recruiting | N/A | 50 | US | Electroconvulsive Therapy (ECT) | Brent Forester, Mayo Clinic, Pine Rest Christian Mental Health Services, Emory University, The Zucker Hillside Hospital, Medical University of South Carolina | Alzheimer Dementia, Agitation,Psychomotor | 05/25 | 05/25 | | |
| Correll, Christoph U |
| Active, not recruiting | 4 | 88 | US | Vortioxetine, Brintellix, Placebo | Northwell Health, Takeda | Schizophrenia, Negative Symptoms | 10/23 | 06/24 | | |
| Not yet recruiting | 3 | 250 | Europe, RoW | CBD 100 mg/mL Oral Solution, Placebo | University of Oxford, Wellcome Trust, GW Pharmaceuticals Ltd, Myonex, Cambridge Cognition Ltd, Premier Research Group plc, Diagram B.V., Cambridgeshire and Peterborough NHS Foundation Trust, Oxford Health NHS Foundation Trust, West London NHS Trust, University of Augsburg, Charite University, Berlin, Germany, University of Cologne, Ludwig Maximilian university of Munich, The Sheba Fund for Health Services and Research, Shalvata Mental Health Center, Geha Mental Health Center, Amsterdam University Medical Center, Hospital General Universitario Gregorio Marañon, National and Kapodistrian University of Athens, Medical University of Vienna, Hospitales Universitarios Virgen del Rocío, University of Campania Luigi Vanvitelli, Swansea University, Psychiatric University Hospital, Zurich, IDEA Regulatory | Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode | 12/27 | 12/28 | | |
NCT01383915: Clinical Risk State for Bipolar Disorder in Adolescents |
|
|
| Active, not recruiting | N/A | 402 | US | | Northwell Health | Bipolar Disorder, Schizophrenia | 12/23 | 12/23 | | |
| Recruiting | N/A | 3331 | Europe | | Charite University, Berlin, Germany, Janssen-Cilag G.m.b.H | Depression, Depression Moderate, Depression Severe, Suicidal and Self-injurious Behavior, Suicidal Ideation, Suicide, Attempted | 12/24 | 12/24 | | |
RESHAPE, NCT05480046: Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse |
|
|
| Recruiting | N/A | 1200 | Europe | Risperidone ISM, OKEDI® | Rovi Pharmaceuticals Laboratories | Schizophrenia | 12/24 | 12/24 | | |
CARE, NCT05813080: Computer-assisted Risk Evaluation in the Early Detection of Psychotic Disorders |
|
|
| Recruiting | N/A | 436 | Europe | "pronia.ai" medical device for high risk psychosis prognosis, Treatment-as-usual (TAU) | Heinrich-Heine University, Duesseldorf | Psychotic Disorders, Prevention | 12/24 | 03/25 | | |
| Not yet recruiting | N/A | 200 | NA | Family based treatment, Inpatient multimodal therapy | Charite University, Berlin, Germany, Bielefeld University, Techniker Krankenkasse, BARMER, AOK Niedersachsen, Mobil Krankenkasse, Meine Krankenkasse, Medicalnetworks CJ GmbH & Co.KG, AOK Baden-Württemberg, DAK Gesundheit, BIG-direkt, mhplus, Bahn-BKK, OFFIS - Institut für Informatik, Prof. Daniel Le Grange, UCSF | Anorexia Nervosa, Anorexia in Adolescence | 03/27 | 12/27 | | |
| Malhotra, Anil K |
ModSoCCS, NCT04418011: Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders |
|
|
| Completed | N/A | 70 | Canada, US | Repetitive Transcranial Magnetic Stimulation, Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation), Repetitive Transcranial Magnetic Stimulation (Sham) | Centre for Addiction and Mental Health, The Feinstein Institutes for Medical Research, University of Maryland School of Medicine, National Institutes of Health (NIH) | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders | 02/23 | 02/23 | | |
NCT02822092: Striatal Connectivity and Clinical Outcome in Psychosis |
|
|
| Completed | N/A | 196 | US | Risperidone or Aripiprazole (patients only), Risperidal, Aripiprazole | Northwell Health, National Institutes of Health (NIH) | Psychotic Disorders | 12/23 | 12/23 | | |
| Braga, Raphael J |
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression |
|
|
| Completed | 2 | 197 | Canada, US | Liafensine, Placebo | Denovo Biopharma LLC | Treatment Resistant Depression | 02/24 | 03/24 | | |
| Kapoor, Sandeep |
| Recruiting | 1 | 230 | US | Observation | NYU Langone Health, National Institutes of Health (NIH) | Opiod Use Disorder | 04/25 | 07/25 | | |
| Gallego, Juan |
ASTARTÉ, NCT04478721: Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins |
|
|
| Recruiting | 3 | 334 | Europe | Temocillin, Meropenem | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Network for Research in Infectious Diseases, SCReN Spanish research Network- CTU-HUVR | Bacteremia | 03/25 | 12/25 | | |
REITAB-2, NCT05204563: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, ) |
|
|
| Recruiting | 3 | 450 | Europe, US, RoW | Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam, Recarbrio | Evopoint Biosciences Inc. | Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | 04/25 | 12/25 | | |
NCT06702449: A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age |
|
|
| Recruiting | 1/2 | 448 | Europe, US, RoW | Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo | GlaxoSmithKline | Urinary Tract Infections | 08/27 | 08/27 | | |
| Argyelan, Miklos |
| Recruiting | 1 | 20 | US | Medtronic SenSight Directional DBS lead | Northwell Health, Medtronic | Treatment Resistant Depression | 10/30 | 10/38 | | |
NCT04763655: Neural Biomarkers of Electroconvulsive Therapy Response |
|
|
| Recruiting | N/A | 75 | US | clinical and neuropsychological testing, MRI of the brain | Northwell Health, National Institutes of Health (NIH) | Electroconvulsive Therapy Treated Patients | 12/24 | 07/25 | | |
| Recruiting | N/A | 50 | US | Reclaim™ DBS Therapy | Northwell Health, Medtronic | Obsessive-Compulsive Disorder (OCD) | 01/30 | 01/30 | | |
| Walsh, Megan |
| Not yet recruiting | N/A | 192 | US | Core Decompression, Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate | Johns Hopkins University, Stanford University, Sinai Hospital of Baltimore, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head | 04/28 | 08/28 | | |
| Azizi, Heela |
NCT03926520: Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) |
|
|
| Recruiting | N/A | 50 | US | Electroconvulsive Therapy (ECT) | Brent Forester, Mayo Clinic, Pine Rest Christian Mental Health Services, Emory University, The Zucker Hillside Hospital, Medical University of South Carolina | Alzheimer Dementia, Agitation,Psychomotor | 05/25 | 05/25 | | |
NCT04763655: Neural Biomarkers of Electroconvulsive Therapy Response |
|
|
| Recruiting | N/A | 75 | US | clinical and neuropsychological testing, MRI of the brain | Northwell Health, National Institutes of Health (NIH) | Electroconvulsive Therapy Treated Patients | 12/24 | 07/25 | | |
| Kirschenbaum, Michael |
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I |
|
|
| Active, not recruiting | N/A | 300 | Canada, US, RoW | ERG assessment (RSPA) | diaMentis Inc. | Schizophrenia, Bipolar I Disorder | 12/24 | 12/24 | | |
